CEO Jeffery Bacha Discusses DelMar Pharma’s VOL-083 Clinical Trials And The Major Milestones Ahead
Published: Sep 26, 2017
VANCOUVER, British Columbia , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Jeffery Bacha, CEO of DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. Mr. Bacha discusses DelMar’s VOL-083 phase 3 clinical trial chemotherapy that has recently launched and how this trial has progressed since its launch. Delmar recently completed a financing, and Mr. Bacha explains how this financing benefits the company and supports DelMar’s clinical trials. Furthermore, Mr. Bacha discusses the major milestones for the future of DelMar and what the company is looking to accomplish with its research and clinical trials.
In closing, CEO Jeffery Bacha states, “There is a wonderful story about a fellow who is a glioblastoma patient and he was treated the Monday, Tuesday and Wednesday prior to the weekend that he and his wife joined us on what’s called The Ride to Concur Cancer. He rode over 250 kilometers from Vancouver British Columbia to Seattle and he’s on our drug and he’s tolerating it very well,” Mr. Bacha continues, “It is amazing to be a part of that with him. Just knowing that this is someone that we are hopefully going to be able to help and being a part of that puts this into perspective of how important this is and we are looking to do that for many more patients.”
To listen to the full interview please click here or the following link: https://upticknewswire.com/interview-ceo-jeffrey-bacha-of-delmar-pharmaceuticals-inc-nasdaq-dmpi
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments.
The Company's current pipeline is based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the NCI. Based on DelMar's internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.
The STAR-3 trial is a multi-center, pivotal, randomized Phase 3 clinical study in bevacizumab (Avastin®) recurrent GBM. Outcomes in DelMar's recent Phase 1-2 clinical trials suggest that VAL-083 may offer a clinically meaningful survival benefit for this patient population.
VAL-083 is also being studied in two collaborator-supported, biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM as a potential alternative for the majority of GBM patients whose tumors exhibit high expression of MGMT, a biomarker correlated with resistance to the current standard-of-care chemotherapy. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM.
The VAL-083 REPROVe trial will explore VAL-083 in platinum-resistant ovarian cancer. Resistance to platinum-based chemotherapy represents a significant unmet medical need in the treatment of ovarian cancer.
Further information on DelMar's clinical trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
Source: Uptick Newswire
For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: email@example.com / (604) 629-5989.